Selected article for: "death disease onset and disease onset"

Author: Tan, Anthony T.; Linster, Martin; Tan, Chee Wah; Le Bert, Nina; Chia, Wan Ni; Kunasegaran, Kamini; Zhuang, Yan; Tham, Christine Y.L.; Chia, Adeline; Smith, Gavin JD.; Young, Barnaby; Kalimuddin, Shirin; Low, Jenny G.H.; Lye, David; Wang, Lin-Fa; Bertoletti, Antonio
Title: Early induction of functional SARS-CoV-2 specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients
  • Cord-id: r7kvv48s
  • Document date: 2021_1_21
  • ID: r7kvv48s
    Snippet: Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. We interrogate the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. We quantify SARS-CoV-2 viral RNA in the respiratory tract in parallel with antibodies and circulating T cells specific for various structural (NP, M, ORF3a and spike) and non-structural proteins (ORF7/8, NSP7
    Document: Virus-specific humoral and cellular immunity act synergistically to protect the host from viral infection. We interrogate the dynamic changes of virological and immunological parameters in 12 patients with symptomatic acute SARS-CoV-2 infection from disease onset to convalescence or death. We quantify SARS-CoV-2 viral RNA in the respiratory tract in parallel with antibodies and circulating T cells specific for various structural (NP, M, ORF3a and spike) and non-structural proteins (ORF7/8, NSP7 and NSP13). While rapid induction and quantity of humoral responses associates with an increase in disease severity, early induction of IFN-γ secreting SARS-CoV-2 specific T cells is present in patients with mild disease and accelerated viral clearance. These findings provide support for the prognostic value of early functional SARS-CoV-2 specific T cells with important implications in vaccine design and immune monitoring.

    Search related documents:
    Co phrase search for related documents
    • acute disease and adaptive immunity component: 1
    • acute disease and additional study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute disease and longitudinal analysis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute disease and longitudinally follow: 1
    • acute disease and luminex analysis: 1
    • acute disease and lung environment: 1, 2
    • acute patient and additional study: 1, 2, 3, 4
    • acute patient and lung environment: 1
    • acute phase and adaptive immunity: 1, 2, 3, 4, 5, 6, 7
    • acute phase and additional study: 1, 2
    • acute phase and longitudinal analysis: 1, 2, 3, 4
    • acute phase and longitudinally follow: 1
    • acute phase and lung environment: 1
    • adaptive immunity and additional study: 1
    • adaptive immunity and longitudinal analysis: 1, 2, 3, 4
    • adaptive immunity and lung environment: 1, 2, 3
    • additional study and longitudinal analysis: 1